Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Roberto Latagliata, Alessandro Andriani, Massimo Breccia, Ida Carmosino, Federico Vozella, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Valerio De Stefano, Marco Montanaro

Blood (2022) 140 (Supplement 1): 9691–9692.

https://doi.org/10.1182/blood-2022-165356

Published: 2022

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 4322.

https://doi.org/10.1182/blood-2019-124645

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group

Federico Vozella, MD, Agostina Siniscalchi, MD, Manuela Rizzo, MD, Tommaso Za, MD, Giusy Antolino, MD, Ugo Coppetelli, MD, Alfonso Piciocchi, Alessandro Andriani, MD, Ombretta Annibali, MD, Luca De Rosa, Giuseppe Cimino, Giacinto La Verde, Valerio De Stefano, MD, Maria Cantonetti, MD, Tommaso Caravita di Toritto, MD, Robin Foà, MD, Maria Teresa Petrucci, MD

Blood (2018) 132 (Supplement 1): 5634.

https://doi.org/10.1182/blood-2018-99-115463

Published: 2018

Journal Articles

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Laura Cesini, MD, Ida Carmosino, Melissa Campanelli, MD, Massimo Breccia, MD, Maria Lucia De Luca, Gioia Colafigli, Matteo Molica, Fulvio Massaro, Federico Vozella, Daniela Diverio, PhD, Marco Mancini, MD, Giuliana Alimena, Roberto Latagliata, MD

Blood (2016) 128 (22): 1903.

https://doi.org/10.1182/blood.V128.22.1903.1903

Published: 2016

Journal Articles

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Roberto Latagliata, MD, Pasquale Niscola, MD, Maria Antonietta Aloe Spiriti, MD, Ida Carmosino, Laura Cesini, MD, Chiara Sarlo, MD, Annalina Piccioni, MD, Alessia Campagna, MD, Maria Lucia De Luca, Federico Vozella, Melissa Campanelli, MD, Marco Mancini, MD, Massimo Breccia, MD, Giuseppe Avvisati, MD, Agostino Tafuri, MD, Paolo de Fabritiis, MD, Giuliana Alimena, MD, Corrado Girmenia, MD

Blood (2016) 128 (22): 5544.

https://doi.org/10.1182/blood.V128.22.5544.5544

Published: 2016

Journal Articles

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Roberto Latagliata, Massimo Breccia, MD, Ida Carmosino, Federico Vozella, Federico De Angelis, Chiara Montagna, Maria Lucia De Luca, Gioia Colafigli, Luisa Quattrocchi, Giovanna Loglisci, Angela Romano, Paola Volpicelli, Daniela Diverio, PhD, Marco Mancini, Giuliana Alimena

Blood (2015) 126 (23): 4038.

https://doi.org/10.1182/blood.V126.23.4038.4038

Published: 2015

Journal Articles

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 3687.

https://doi.org/10.1182/blood.V124.21.3687.3687

Published: 2014

Journal Articles

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Blood (2014) 124 (21): 5326.

https://doi.org/10.1182/blood.V124.21.5326.5326

Published: 2014

Journal Articles

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 1063.

https://doi.org/10.1182/blood.V124.21.1063.1063

Published: 2014

Journal Articles

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Roberto Latagliata, MD, Ida Carmosino, Federico Vozella, Paola Volpicelli, MD, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, MD, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, PhD, Mauro Nanni, PhD, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena, MD

Blood (2013) 122 (21): 4002.

https://doi.org/10.1182/blood.V122.21.4002.4002

Published: 2013

Journal Articles

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Paola Volpicelli, MD, Roberto Latagliata, MD, Massimo Breccia, Federico Vozella, Paola Finsinger, Ida Carmosino, Giuseppina Loglisci, MD, Michelina Santopietro, MD, Adriano Salaroli, Daniela Diverio, PhD, Marco Mancini, MD, Agostino Tafuri, Giuliana Alimena

Blood (2012) 120 (21): 3769.

https://doi.org/10.1182/blood.V120.21.3769.3769

Published: 2012

Journal Articles

Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience

Blood (2012) 120 (21): 4958.

https://doi.org/10.1182/blood.V120.21.4958.4958

Published: 2012

Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena

Blood (2011) 118 (21): 3783.

https://doi.org/10.1182/blood.V118.21.3783.3783

Published: 2011

Journal Articles

Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients

Roberto Latagliata, Agostino Tafuri, Antonio Spadea, Antonietta Ferretti, Daniela Diverio, Massimo Breccia, Mariella D'Andrea, Alessandro Andriani, Marco Montanaro, Michele Cedrone, Enrico Montefusco, Angela Rago, M.D., Odoardo Maria Olimpieri, Antonino Bagnato, MD, Francesca Biondo, Federico Vozella, Maria Cantonetti, MD, Maria Concetta Petti, MD, Giuliana Alimena

Blood (2011) 118 (21): 5172.

https://doi.org/10.1182/blood.V118.21.5172.5172

Published: 2011

Journal Articles

Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?

Roberto Latagliata, MD, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Caterina Stefanizzi, Michelina Santopietro, Rosa De Cuia, Mauro Nanni, Marco Mancini, Giuliana Alimena

Blood (2009) 114 (22): 4271.

https://doi.org/10.1182/blood.V114.22.4271.4271

Published: 2009

Journal Articles

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

Paola Finsinger, Massimo Breccia, Clara Minotti, Ida Carmosino, Laura Cannella, Paola Volpicelli, Federico Vozella, Caterina Stefanizzi, Giuseppina Loglisci, Giuseppe Cimino, Robin Foà, Roberto Latagliata, MD

Blood (2009) 114 (22): 4160.

https://doi.org/10.1182/blood.V114.22.4160.4160

Published: 2009

Journal Articles

Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.

Ida Carmosino, Roberto Latagliata, MD, Massimo Breccia, Laura Cannella, Federico Vozella, Paola Volpicelli, Michelina Santopietro, Antonio Spadea, MD, PhD, Maria Concetta Petti, Giuliana Alimena

Blood (2009) 114 (22): 4985.

https://doi.org/10.1182/blood.V114.22.4985.4985

Published: 2009

Journal Articles

Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib

Roberto Latagliata, Massimo Breccia, Fabio Stagno, Silvia De Matteis, Mario Annunziata, Ida Carmosino, Laura Cannella, Laura Napoleone, Federico Vozella, Simona Sica, Francesco Di Raimondo, MD, Felicetto Ferrara, Giuliana Alimena

Blood (2008) 112 (11): 4253.

https://doi.org/10.1182/blood.V112.11.4253.4253

Published: 2008

NARROW

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group

Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib

Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients

Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.

Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only